Phase 1 Study of MPC-3100 in Patients With Refractory or Relapsed Cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2011
At a glance
- Drugs MPC 3100 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 14 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Myrexis media release.
- 09 Nov 2011 Final results are expected before the end of November 2011, according to a Myrexis media release.
- 08 Sep 2011 Status changed from active, no longer recruiting to completed, as reported in a Myrexis media release